Key Takeaways
- Novo Nordisk received an FDA warning letter on March 5 for failing to properly report adverse events associated with semaglutide, found in Ozempic and Wegovy.
- The letter referenced three fatalities — one being a suicide — with the FDA noting the company failed to investigate or report the suicide within required timelines.
- The pharmaceutical giant has a two-week deadline to outline corrective measures to the FDA.
- Novo maintains the warning won’t affect manufacturing operations or its current investor guidance.
- Shares of NVO have declined 27% in 2026, currently hovering near $38.32.
Novo Nordisk’s challenging year continues to worsen with fresh regulatory complications.
On March 5, the FDA delivered a warning letter to the Copenhagen-based pharmaceutical company, highlighting “serious violations” concerning its handling of adverse event reporting for semaglutide, the compound used in both Ozempic and Wegovy.
These infractions came to light during a facility inspection conducted at Novo Nordisk’s New Jersey location in the previous year.
The warning letter specifically mentioned three fatalities, which included two deaths and one suicide. According to the FDA, Novo Nordisk neglected to properly investigate or file a report on the suicide case within mandated deadlines.
It’s important to note that the FDA has not established a causal relationship between these medications and the reported deaths. The agency’s primary concern centers on procedural compliance in reporting protocols.
“FDA relies on the complete, accurate, and timely submission of ADEs to monitor a product’s safety profile,” the regulatory body stated, referencing adverse drug events.
Novo Nordisk now has a 14-day window to inform the FDA about corrective measures it intends to implement.
In a public statement, the drugmaker indicated it has been working “diligently” to resolve the FDA’s concerns. The company confirmed submitting an initial response along with seven subsequent updates to the agency.
Novo also confirmed that the flagged cases “have been evaluated” and are now “processed and reported appropriately.” However, the company stopped short of disputing that it had initially failed to report them correctly.
Mounting Regulatory Challenges
This latest incident isn’t Novo’s first regulatory stumble in recent months. In December, the FDA sent another warning letter to the company’s Bloomington, Indiana manufacturing site regarding Good Manufacturing Practice violations.
Additionally, last month the FDA dispatched two separate letters condemning marketing materials for Ozempic and Wegovy for containing “false or misleading claims” about effectiveness and safety. A February 26 correspondence specifically accused Novo of positioning Ozempic as superior to rival medications without adequate substantiation.
In its press statement, Novo addressed the recurring issues, simply stating: “We work in a highly regulated space.”
The pharmaceutical company insists the most recent warning won’t disrupt production schedules or alter the financial projections it has shared with investors.
Shares Plunge 27% This Year
NVO shareholders have endured a difficult 2026. Trading around $38.32, the stock has tumbled 27% year to date, significantly below previous peak levels.
The decline stems from multiple factors — intensifying regulatory scrutiny and fierce competition from Eli Lilly’s rival GLP-1 medication Mounjaro have both dampened investor confidence.
Political obstacles have compounded the pressure. Health Secretary RFK Jr. has openly denounced Ozempic as excessively expensive, and previously blocked a Biden administration initiative that would have extended Medicare coverage for GLP-1 medications to approximately 7 million Americans.
As of Tuesday afternoon, the stock remained at $38.32.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
